RE:MM wants disappointed investors to know he doesn't like them Yada yada yada.
ex-investors tend to be emotional and ignore the facts. And of course many of them are not real - they're more like plants. ( plants are living of course but they're more like decorations for the corner that require the occasional watering.)
Rather than posters & personalities, I prefer to go by the facts, that despite some keystone coppery, and dare I say greed, displayed along the way by Mgt and the bored of directing, still leads the thoughtful LT investor to an inescapable conclusion.
- - Improving pace of enrollment (finally) over several months, and post Investigators Meeting and new CRO appointment.
-
- - Much higher usage ( post approval) is now anticipated based on the number of patients coming forward as possible PMX candidates (but that don't meet the strict Trial criteria). Suggests an even more dramatic undervaluation ( in relation to discounted future cash flows)
- - Phase 3b confirmatory Trial that continues to "exceed expectations" (I wonder, when do we hit statistical certainty of "confirmation", for the Trial as a whole?)
- - No reason to expect that Baxter (the presumed multi-billion $ Distributor who has already ponied up millions) won't pony up millions more before or shortly after year end, thereby financing a good portion of the remaining trial costs.
- - And of course the possibility of early stoppage given statistics, overwhelming need ( see high death rates), newly published Euphas 2 results, and ethics in an open label Trial environment.
MM